Combining discovery and targeted proteomics reveals a prognostic signature in oral cancer

Carregando...
Imagem de Miniatura
Citações na Scopus
125
Tipo de produção
article
Data de publicação
2018
Título da Revista
ISSN da Revista
Título do Volume
Editora
NATURE PUBLISHING GROUP
Autores
CARNIELLI, Carolina Moretto
MACEDO, Carolina Carneiro Soares
ROSSI, Tatiane De
GRANATO, Daniela Campos
RIVERA, Cesar
DOMINGUES, Romenia Ramos
PAULETTI, Bianca Alves
YOKOO, Sami
HEBERLE, Henry
BUSSO-LOPES, Ariane Fidelis
Citação
NATURE COMMUNICATIONS, v.9, article ID 3598, 17p, 2018
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Different regions of oral squamous cell carcinoma (OSCC) have particular histopathological and molecular characteristics limiting the standard tumor-node-metastasis prognosis classification. Therefore, defining biological signatures that allow assessing the prognostic outcomes for OSCC patients would be of great clinical significance. Using histopathology-guided discovery proteomics, we analyze neoplastic islands and stroma from the invasive tumor front (ITF) and inner tumor to identify differentially expressed proteins. Potential signature proteins are prioritized and further investigated by immunohistochemistry (IHC) and targeted proteomics. IHC indicates low expression of cystatin-B in neoplastic islands from the ITF as an independent marker for local recurrence. Targeted proteomics analysis of the prioritized proteins in saliva, combined with machine-learning methods, highlights a peptide-based signature as the most powerful predictor to distinguish patients with and without lymph node metastasis. In summary, we identify a robust signature, which may enhance prognostic decisions in OSCC and better guide treatment to reduce tumor recurrence or lymph node metastasis.
Palavras-chave
Referências
  1. Alfonso P, 2008, J PROTEOME RES, V7, P4247, DOI 10.1021/pr800152u
  2. Almangush A, 2015, INT J ORAL MAX SURG, V44, P143, DOI 10.1016/j.ijom.2014.10.004
  3. Arduino PG, 2008, J ORAL MAXIL SURG, V66, P1570, DOI 10.1016/j.joms.2007.12.024
  4. Barnes L., 2005, WHO CLASSIF TUMOUR, P163, DOI [10.1016/j.urology.2004.09.048, DOI 10.1016/J.UROLOGY.2004.09.048]
  5. Batista G.E.A.P.A., 2004, ACM SIGKDD EXPL NEWS, V6, P20, DOI 10.1145/1007730.1007735
  6. BENJAMINI Y, 1995, J ROY STAT SOC B MET, V57, P289
  7. Brandwein-Gensler A, 2005, AM J SURG PATHOL, V29, P167
  8. Brandwein-Gensler M., 2010, AM J SURG PATHOL, V34, P1
  9. BRYNE M, 1992, J PATHOL, V166, P375, DOI 10.1002/path.1711660409
  10. BRYNE M, 1989, J ORAL PATHOL MED, V18, P432, DOI 10.1111/j.1600-0714.1989.tb01339.x
  11. Bu JQ, 2015, MED SCI MONITOR, V21, P2275, DOI 10.12659/MSM.893925
  12. Costa LCMC, 2015, J APPL ORAL SCI, V23, P169, DOI 10.1590/1678-775720140187
  13. Carvalho AL, 2005, OTOLARYNG HEAD NECK, V132, P862, DOI 10.1016/j.otohns.2005.01.034
  14. Chawla NV, 2002, J ARTIF INTELL RES, V16, P321, DOI 10.1613/jair.953
  15. Chen PW, 2013, TRENDS MOL MED, V19, P410, DOI 10.1016/j.molmed.2013.04.001
  16. Chen X, 2004, CURR CANCER DRUG TAR, V4, P267, DOI 10.2174/1568009043333041
  17. Chi LM, 2009, MOL CELL PROTEOMICS, V8, P1453, DOI 10.1074/mcp.M800460-MCP200
  18. Chung LC, 2012, AM J PHYSIOL-CELL PH, V302, pC676, DOI 10.1152/ajpcell.00180.2011
  19. Cox J, 2011, J PROTEOME RES, V10, P1794, DOI 10.1021/pr101065j
  20. Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511
  21. Curry JM, 2014, SEMIN ONCOL, V41, P217, DOI 10.1053/j.seminoncol.2014.03.003
  22. da Silva SD, 2015, ONCOTARGET, V6, P21950, DOI 10.18632/oncotarget.4277
  23. da Silva SD, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00149
  24. DeBerardinis RJ, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1600200
  25. Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434-010-0985-4
  26. Fan S, 2011, INT J ORAL SCI, V3, P180, DOI 10.4248/IJOS11068
  27. Fang BA, 2014, BBA-REV CANCER, V1845, P1, DOI 10.1016/j.bbcan.2013.11.002
  28. Feldman AS, 2009, CLIN CANCER RES, V15, P1024, DOI 10.1158/1078-0432.CCR-08-1143
  29. Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
  30. Flores IL, 2016, CLIN SCI, V130, P785, DOI 10.1042/CS20150646
  31. Gallien S, 2011, J MASS SPECTROM, V46, P298, DOI 10.1002/jms.1895
  32. Ganly I, 2012, CANCER-AM CANCER SOC, V118, P101, DOI 10.1002/cncr.26229
  33. Greenberg JS, 2003, CANCER, V98, P508, DOI 10.1002/cncr.11526
  34. Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
  35. Harris TM, 2015, ARCH PATHOL LAB MED, V139, P494, DOI 10.5858/arpa.2014-0131-OA
  36. Heberle H, 2015, BMC BIOINFORMATICS, V16, DOI 10.1186/s12859-015-0611-3
  37. Ho AS, 2017, J CLIN ONCOL, V35, P3601, DOI 10.1200/JCO.2016.71.1176
  38. Hubner NC, 2010, J CELL BIOL, V189, P739, DOI 10.1083/jcb.200911091
  39. Hwang TL, 2006, PROTEOMICS, V6, P2259, DOI 10.1002/pmic.200500345
  40. Jensen DH, 2015, J PATHOL, V236, P505, DOI 10.1002/path.4550
  41. Jin H, 2004, BRIT J CANCER, V90, P561, DOI 10.1038/sj.bjc.6601576
  42. Kawahara R, 2016, PROTEOMICS, V16, P159, DOI 10.1002/pmic.201500224
  43. Kim Y, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11906
  44. Lagani V., 2016, J STAT SOFTW, V25
  45. Lange V, 2008, MOL SYST BIOL, V4, DOI 10.1038/msb.2008.61
  46. Larsen SR, 2009, J ORAL PATHOL MED, V38, P657, DOI 10.1111/j.1600-0714.2009.00797.x
  47. Levicar N, 2002, CANCER DETECT PREV, V26, P42, DOI 10.1016/S0361-090X(02)00015-6
  48. Lu JG, 2011, J CANCER RES CLIN, V137, P1613, DOI 10.1007/s00432-011-1024-y
  49. MacLean B, 2010, BIOINFORMATICS, V26, P966, DOI 10.1093/bioinformatics/btq054
  50. Maere S, 2005, BIOINFORMATICS, V21, P3448, DOI 10.1093/bioinformatics/bti551
  51. Marakalala MJ, 2016, NAT MED, V22, P531, DOI 10.1038/nm.4073
  52. McShane LM, 2006, BREAST CANCER RES TR, V100, P229, DOI 10.1007/s10549-006-9242-8
  53. Mehanna H, 2016, NEW ENGL J MED, V374, P1
  54. Meng WX, 2014, CANCER RES, V74, P2306, DOI 10.1158/0008-5472.CAN-13-2275
  55. Noguti J, 2012, CANCER GENOM PROTEOM, V9, P329
  56. Oi N, 2017, CARCINOGENESIS, V38, P728, DOI 10.1093/carcin/bgx049
  57. Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394
  58. Rappsilber J, 2007, NAT PROTOC, V2, P1896, DOI 10.1038/nprot.2007.261
  59. Rodrigues PC, 2015, ONCOL LETT, V9, P667, DOI 10.3892/ol.2014.2763
  60. Romanska HM, 2013, ORAL ONCOL, V49, P224, DOI 10.1016/j.oraloncology.2012.09.013
  61. Sabatelli P, 2001, MATRIX BIOL, V20, P475, DOI 10.1016/S0945-053X(01)00160-3
  62. Saito R, 2012, NAT METHODS, V9, P1069, DOI [10.1038/NMETH.2212, 10.1038/nmeth.2212]
  63. Salo T, 2014, EXP CELL RES, V325, P58, DOI 10.1016/j.yexcr.2013.12.029
  64. Sawazaki-Calone I, 2015, ORAL DIS, V21, P755, DOI 10.1111/odi.12343
  65. Schaaij-Visser TBM, 2009, CLIN CANCER RES, V15, P7666, DOI 10.1158/1078-0432.CCR-09-2134
  66. Scully C, 2009, ORAL ONCOL, V45, P301, DOI 10.1016/j.oraloncology.2009.01.004
  67. Sharma Mohit, 2013, J Oral Maxillofac Pathol, V17, P240, DOI 10.4103/0973-029X.119740
  68. Sundquist E, 2017, BRIT J CANCER, V116, P640, DOI 10.1038/bjc.2016.455
  69. Tlsty TD, 2006, ANNU REV PATHOL-MECH, V1, P119, DOI 10.1146/annurev.pathol.1.110304.100224
  70. Tsai JH, 2013, GENE DEV, V27, P2192, DOI 10.1101/gad.225334.113
  71. Turk V, 2008, FRONT BIOSCI-LANDMRK, V13, P5406, DOI 10.2741/3089
  72. Turley SJ, 2015, NAT REV IMMUNOL, V15, P669, DOI 10.1038/nri3902
  73. van der Waal I, 2013, MED ORAL PATOL ORAL, V18, pE33, DOI 10.4317/medoral.18486
  74. Villen J, 2008, NAT PROTOC, V3, P1630, DOI 10.1038/nprot.2008.150
  75. Vizcaino JA, 2014, NAT BIOTECHNOL, V32, P223, DOI 10.1038/nbt.2839
  76. Waisberg J, 2014, ANTICANCER RES, V34, P5599
  77. Wang YH, 2015, CANCER BIOMARK, V15, P213, DOI 10.3233/CBM-150464
  78. Winck FV, 2015, SCI REP-UK, V5, DOI 10.1038/srep16305
  79. Xie N, 2015, J ORAL PATHOL MED, V44, P266, DOI 10.1111/jop.12242
  80. Zhang J, 2016, ONCOL RES, V24, P487, DOI 10.3727/096504016X14685034103752